Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Virology

• Publication date

  1997-04-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/VIRO.1997.8465PMID 9143271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties.

  1997cited by this paper
• Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor.

  1996cited by this paper
• Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein.

  1996cited by this paper
• Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus

  1996cited by this paper
• Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.

  1995cited by this paper
• Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus.

  1995cited by this paper
• Hydrophobicity engineering to facilitate surface display of heterologous gene products on Staphylococcus xylosus.

  1995cited by this paper
• Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin.

  1995cited by this paper
• Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

  1995cited by this paper
• Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection.

  1995cited by this paper
• Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein

  1995cited by this paper
• Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit.

  1994cited by this paper
• Bacterial expression of human respiratory syncytial viral phosphoprotein P and identification of Ser237 as the site of phosphorylation by cellular casein kinase II.

  1994cited by this paper
• Distinct types of lung disease caused by functional subsets of antiviral T cells

  1994cited by this paper
• Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation.

  1994cited by this paper
• Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus.

  1994cited by this paper
• Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein

  1994cited by this paper
• Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations).

  1994cited by this paper
• An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.

  1994cited by this paper
• Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.

  1993cited by this paper
• Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.

  1993cited by this paper
• Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.

  1993cited by this paper
• Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.

  1992cited by this paper
• Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.

  1992cited by this paper
• The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity.

  1991cited by this paper
• Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells

  1991cited by this paper
• Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses.

  1991cited by this paper
• Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope.

  1991cited by this paper
• Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.

  1991cited by this paper
• Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses

  1991cited by this paper
• Japanese Encephalitis Virus Fusion Protein with Protein A Expressed in Escherichia coli Confers Protective Immunity in Mice

  1991cited by this paper
• Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

  1990cited by this paper
• A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop

  1990cited by this paper
• The respiratory syncytial virus subgroup B attachment glycoprotein: analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge.

  1990cited by this paper
• Expression in Escherichia coli of the large genomic segment of infectious pancreatic necrosis virus.

  1990cited by this paper
• Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus

  1989cited by this paper
• Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections

  1989cited by this paper
• Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.

  1989cited by this paper
• A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA.

  1989cited by this paper
• The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.

  1988cited by this paper
• Analysis and use of the serum albumin binding domains of streptococcal protein G

  1988cited by this paper
• Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells.

  1987cited by this paper
• Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity

  1987cited by this paper
• Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats

  1987cited by this paper
• Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus

  1987cited by this paper
• Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.

  1987cited by this paper
• Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

  1986cited by this paper
• Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge

  1986cited by this paper
• Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response

  1986cited by this paper
• Two distinct subtypes of human respiratory syncytial virus.

  1985cited by this paper
• Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus.

  1985cited by this paper
• Respiratory syncytial virus infection in mice

  1984cited by this paper
• Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

  1984cited by this paper
• A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody.

  1984cited by this paper
• Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens.

  1984cited by this paper
• Activation of mouse complement by different classes of mouse antibody.

  1979cited by this paper
• Biological activities of immunoglobulins of different classes and subclasses.

  1974cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969cited by this paper
• Techniques in Experimental Virology

  1965cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Myoferlin is a component of late-stage vRNP trafficking vesicles for enveloped RNA viruses.

  2026cites this paper
• Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection

  2024influential citation
• Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.

  2023cites this paper
• Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model.

  2022cites this paper
• Inhibition of the TLR4 signalling pathway with TAK-242 reduces RSV infection and cytokine release in primary airway epithelial cells

  2021cites this paper
• A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease

  2021cites this paper
• Identification of antigenic epitopes on the F and G glycoproteins of bovine respiratory syncytial virus and in vitro assessment of their synthetic peptide vaccine potential

  2021cites this paper
• An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells

  2021cites this paper
• Up-to-date role of biologics in the management of respiratory syncytial virus

  2020cites this paper
• Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media

  2020cites this paper
• Engineered Protein Scaffolds as Next-Generation Therapeutics.

  2020cites this paper
• Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies.

  2020cites this paper
• Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures

  2019cites this paper
• Development and application of a higher throughput RSV plaque assay by immunofluorescent imaging.

  2019cites this paper
• Hurdles in Vaccine Development against Respiratory Syncytial Virus

  2019cites this paper
• Original Antigenic Sin and Respiratory Syncytial Virus Vaccines

  2019cites this paper
• Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures

  2019cites this paper
• The Role of Toll-like receptor 4 in respiratory syncytial virus replication, interferon lambda 1 induction, and chemokine responses

  2018cites this paper
• Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

  2017cites this paper
• Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge

  2017cites this paper
• Recent advances in the development of subunit-based RSV vaccines

  2016cites this paper
• Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses

  2016cites this paper
• Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay.

  2016cites this paper
• Human Respiratory Syncytial Virus: Role of Innate Immunity in Clearance and Disease Progression

  2016cites this paper
• Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels

  2015cites this paper
• A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA-SE Elicits Robust Protective TH1-Type Humoral and Cellular Immunity In Rodent Models

  2015cites this paper
• Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium

  2015cites this paper
• Structure and Function of RSV Surface Glycoproteins

  2014cites this paper
• Development of Safe and Effective RSV Vaccine by Modified CD4 Epitope in G Protein Core Fragment (Gcf)

  2014cites this paper
• respiratory syncytial virus ( RSV ) vaccine based on parainfluenza irus 5 ( PIV 5 )

  2014cites this paper
• Neonatal Immunization with Respiratory Syncytial Virus Glycoprotein Fragment Induces Protective Immunity in the Presence of Maternal Antibodies in Mice

  2013cites this paper
• Structure and function of respiratory syncytial virus surface glycoproteins.

  2013cites this paper
• Subunit Vaccine Candidates Engineered from the Central Conserved Region of the RSV G Protein Aimed for Parenteral or Mucosal Delivery

  2013cites this paper
• Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium.

  2013cites this paper
• Interleukin-27 Inhibits Vaccine-Enhanced Pulmonary Disease following Respiratory Syncytial Virus Infection by Regulating Cellular Memory Responses

  2012cites this paper
• The Respiratory Syncytial Virus G Protein Conserved Domain Induces a Persistent and Protective Antibody Response in Rodents

  2012cites this paper
• Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains

  2012influential citation
• Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant

  2012cites this paper
• Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells

  2011cites this paper
• Dynamics of the bacterially expressed conserved immunogenic region of the human respiratory syncytial virus G protein

  2011cites this paper
• Respiratory syncytial virus vaccine development

  2011cites this paper
• Expression and characterization of a multivalent human respiratory syncytial virus protein

  2010influential citation
• Surface display of respiratory syncytial virus glycoproteins in Lactococcus lactis NZ9000

  2010cites this paper
• Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice

  2009cites this paper
• Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.

  2009cites this paper
• Respiratory syncytial virus vaccine development.

  2009cites this paper
• Challenges in developing a pediatric RSV vaccine

  2009cites this paper
• Novel therapies for an old virus: treatment of RSV infections in the 21st Century

  2009cites this paper
• Respiratory syncytial virus and parainfluenza virus vaccines

  2008cites this paper
• Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.

  2008cites this paper
• Truncated Recombinant Puumala Virus Nucleocapsid Proteins Protect Mice Against Challenge in Vivo

  2008cites this paper
• Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice.

  2008cites this paper
• Immunopathology of RSV infection: prospects for developing vaccines without this complication

  2007cites this paper
• Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection

  2007cites this paper
• Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats

  2007cites this paper
• Virus respiratorio sincitial, metapneumovirus y virus parainfluenza humanos. IV. Tratamiento y prevención

  2007cites this paper
• Mice and Cotton Rats Induce Protective Mucosal Responses in Syncytial Virus Surface Glycoproteins Replicon Particles Encoding Respiratory Venezuelan Equine Encephalitis Virus

  2007cites this paper
• Respiratory Syncytial Virus NS1 Protein Degrades STAT2 by Using the Elongin-Cullin E3 Ligase

  2007cites this paper
• Virus respiratoire syncytial, métapneumovirus et virus para-influenza humains. IV. Traitement et prévention

  2006cites this paper
• Vaccines against Human Respiratory Syncytial Virus

  2006cites this paper
• Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope.

  2006cites this paper
• Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G.

  2006cites this paper
• Truncated Recombinant Dobrava Hantavirus Nucleocapsid Proteins Induce Strong, Long-Lasting Immune Responses in Mice

  2006cites this paper
• Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response.

  2005cites this paper
• Mapping of B-cell epitopes on the fusion protein of human respiratory syncytial virus.

  2004cites this paper
• Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.

  2004cites this paper
• New drugs and treatment for respiratory syncytial virus

  2004cites this paper
• Role of molecular evolution in respiratory syncytial virus antigenic proteins during annual epidemics in South Africa

  2004cites this paper
• immunogenic complex method of preparing them and their use in pharmaceutical compositions

  2004cites this paper
• Vaccines for the prevention of respiratory viral infections: problems and current status

  2004cites this paper
• A simplified plaque assay for respiratory syncytial virus--direct visualization of plaques without immunostaining.

  2004cites this paper
• Current research on respiratory viral infections: Fifth International Symposium

  2004cites this paper
• The future of respiratory syncytial virus vaccine development

  2004cites this paper
• Detection of Puumala Hantavirus Antibody with ELISA Using a Recombinant Truncated Nucleocapsid Protein Expressed in Escherichia coli

  2004cites this paper
• Synthesis, refolding and protective immune responses of a potential antigen for human Respiratory Syncytial Virus vaccine.

  2003cites this paper
• Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.

  2003cites this paper
• Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate.

  2003cites this paper
• Respiratory Syncytial Virus

  2003cites this paper
• The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.

  2003influential citation
• Protein engineering to explore and improve affinity ligands

  2003cites this paper
• Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV).

  2003cites this paper
• The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B.

  2003cites this paper
• Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G.

  2002cites this paper
• Gamma Interferon-Dependent Protection of the Mouse Upper Respiratory Tract following Parenteral Immunization with a Respiratory Syncytial Virus G Protein Fragment

  2002cites this paper
• DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.

  2002cites this paper
• Current concepts on active immunization against respiratory syncytial virus for infants and young children

  2002cites this paper
• Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge.

  2002cites this paper
• Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus.

  2001cites this paper
• Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults.

  2001cites this paper
• Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens.

  2001cites this paper
• Differential Histopathology and Chemokine Gene Expression in Lung Tissues following Respiratory Syncytial Virus (RSV) Challenge of Formalin-Inactivated RSV- or BBG2Na-Immunized Mice

  2001cites this paper
• Antiviral Activity and Structural Characteristics of the Nonglycosylated Central Subdomain of Human Respiratory Syncytial Virus Attachment (G) Glycoprotein*

  2001cites this paper
• BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.

  2001cites this paper
• Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein.

  2001cites this paper
• The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3

  2001cites this paper
• A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine.

  2001cites this paper
• Current research on respiratory viral infections: Fourth International Symposium

  2001cites this paper
• Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine recovered using a product‐specific affinity column

  2001cites this paper
• Residual DNA quantification in clinical batches of BBG2Na, a recombinant subunit vaccine against human respiratory syncytial virus.

  2001cites this paper
• Respiratory syncytial virus vaccine development.

  2001cites this paper